期刊文献+

放疗加紫杉醇治疗胃癌的临床观察 被引量:1

Radiotherapy and Concomitant Weekly Paclitaxel for Gastric Cancer
下载PDF
导出
摘要 目的探讨常规放疗加紫杉醇治疗胃癌的临床效果及毒副反应。方法回顾性分析我院2005年2月—2006年11月进行常规放疗加每周紫杉醇治疗的胃癌患者35例,放射治疗每周5次,每次1.8 Gy,总剂量43.2 Gy,对于残存肿瘤加量至50.4 Gy。紫杉醇每周1次,40 mg/m2,持续静滴3 h。结果35例按计划完成了治疗,总有效率为80%,1年总生存率为74%。放射性食管炎及胃炎是最常见的毒性反应,Ⅲ级6人(17%),Ⅳ级5人(14%)。结论常规放疗加紫杉醇治疗胃癌是有效的治疗方法,局部控制率好,毒副反应能够耐受,但远处转移的控制有待更进一步的研究。 Objective To evaluate the clinical effect and toxicity of radiotherapy and concomitant weekly paclitaxel for gastric cancer. Methods Thrity-five patients with gastric cancer, who were treated with radiotherapy and concomitant weekly paclitaxel between February 2005 and November 2006, were retrospectively analyzed. The patients, with a mean age of 51 (31 -81 ) years, consisted of 27 males and 8 females. Radiotherapy was administered with conventional technique, i.e. 1.8 Gy/day for 5 days/ week up to a total dosage of 43.2 Gy. Those who were medically inoperable received a radiation boost to 50.4 Gy. The dose of paclitaxel was 40 mg/m^2 once weekly ( intravenous drip over 3 hours). Results Chemoradiotherapy was completed on 35 patients. The overall response rate was 80%. The 1-year survival rate was 74%. Esophagitis and gastritis were the two most important toxicity reactions [ Grade 3 in four patients ( 15 % ), Grade 4 in three patients ( 11% ) ]. Conclusion Radiotherapy plus concomitant weekly paclitaxel is one of the safe and effective treatments for gastric cancer. It can revelive clinical sysptoms, and be well tolerated without severe side effects. The long term complications need to he further studied.
机构地区 解放军第
出处 《临床军医杂志》 CAS 2008年第6期927-929,共3页 Clinical Journal of Medical Officers
关键词 胃肿瘤 紫杉醇 放射治疗 gastric neoplasm paclitaxel radiotherapy
  • 相关文献

参考文献10

  • 1周际昌.实用内科学[M].第2版,北京:人民卫生出版社:2003,591.592.
  • 2Moertel C, Childs D, Reiemeir R, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unreseetable gastrointestinal cancer[ J]. Lancet, 1969,2L :865 - 867.
  • 3Choy H, Rodriguez FF, Koester S, et al. Investigation of taxol as a potential radiation sensitizer [ J ]. Cancer, 1993,71 : 3774 - 3778.
  • 4Liebmann J, Cook JA, Fisher J, et al. In vitro studies of taxol as a radiation sensitizer in human tumor sells[ J]. J Nail Cancer Inst, 1994,86:441 -446.
  • 5Gupta N, Hu LJ, Deen DF. Cytotoxicity and cell-cycle effects of paclitaxe| when used as a single agent and in combination with ionizing radiation [ j ]. Int J Radiat Oncol Biol Phys, 1997,37 :885 -895.
  • 6Lowe SW. Boids S, Mcelatchcy A, et al. p53 status and the efficacy of cancer therapy in vivo [ J]. Science, 1994,226 : 807 - 810.
  • 7Natsume T, Kobayashi M, Fujimoto S. Association of p53 gene muta-tions with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma [ J ]. Cancer, 2001,92 ( 2 ) : 386 - 394.
  • 8Saffan H, King T, Choy H, et al. p53 mutations do not predict response to paelitaxel/radiation for nonsmall cell lung carcinoma [J]. Cancer, 1996,78(6) :1203 - 1210.
  • 9陈明,吴少雄,陈媛媛,林焕新,冼超贵,邓小武,卢泰祥,崔念基.常规放疗加每周紫杉醇治疗局部晚期鼻咽癌的临床Ⅰ期试验[J].中国癌症杂志,2002,12(3):245-248. 被引量:14
  • 10Mason KA, Milas L, Peters LJ. Effect of paclitaxe (taxol) alone and in combination with radiation of the gastrointestinal muesoa [ J]. lnt J Radiat Oncol Biol Phvs, 1995,32 : 1381 - 1389.

二级参考文献14

  • 1[1]Adelstein DJ, Kalish LA, Adams GL, et al.Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study [J]. J Clin Oncol, 1993, 11(11):2136-2142.
  • 2[2]McGuir WP, Rowinsk EK, Rosenhein NB, et al.Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelia neoplasms [J]. Ann Intern Med,1989,111(1):273-279.
  • 3[3]Holm FA, Walters RS, Thierault RL, et al.Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer [J]. J Natl Cancer Inst,1991,83(24):1797-1805.
  • 4[4]Chang AY, Kim K, Glick J, et al.Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study [J]. J Natl Cancer Inst,1993,85(5):388-394.
  • 5[5]Leonard CE, Chan DC, Chou TC, et al. Paclitaxel enhances in vitra radiation sensitivity of squamous carcinoma cell lines of the head neck [J]. Cancer Res,1996,56(22):5189-5204.
  • 6[6]Milas L, Hunter NR, Mason KA, et al. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel [J]. Cancer Res,1997,55(16):3564-3568.
  • 7[7]Ajani JA, Ilson DH, Dougherty K, et al: Paclitaxel in the treatment of carcinoma of the esophagus [J]. Semin Oncol,1995,22(Suppl 6): 3540-3545.
  • 8[8]Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer [J]. J Natl Cancer Inst,1993,85(5):384-388.
  • 9[9]Forastiere AA, Neuberg D, Taylor SG.Phase II evaluation of taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group pilot study [J]. J Natl Cancer Inst Monogr,1993,15(1):181-184.
  • 10[10]Hoffmann W, Belka C, Schmidberger H, et al. Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer-results from a phase I trial [J]. Int J Radiat Oncol Biol Phys,1997,38(4): 691-696.

共引文献13

同被引文献11

  • 1张秀凤,王益民,李琰,郭炜,王娜,王瑞,魏丽珍,葛晖,曹延延,张健慧.CDH1基因3’非编码区单核苷酸多态性与食管癌、贲门癌的关系[J].实用诊断与治疗杂志,2007,21(4):241-244. 被引量:8
  • 2殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].4版.北京:中国协和医科大学出版社,2007:809.
  • 3Balandraud P, Moutardier V, Giovannini M, et al. Locally advanced adenocarcinomas of the gastric cardia: results of preoperative chemoradiotherapy[J]. Gastroenterol Clin Biol,2004, 28(9):651-657.
  • 4Kurokawa Y, Sasako M. Recent advances in chemotherapy and chemoradiotherapy for gastrointestinal tract cancers: adjuvant chemoradiotherapy for gastric eancer[J]. Int J Clin Oncol,2008, 13(6):479-482.
  • 5Stahl M, Walz M K, Stuschke M, et al. Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J]. J Clin Oncol,2009,27(6):851-856.
  • 6Willett C G, Czito B G. Chemoradiotherapy in gastrointestinal malignancies[J]. Clin Oncol (R Coll Radiol), 2009,21 (7): 543-556.
  • 7Kundel Y, Levitt M L, Oberman B, et al. Adjuvant chemotherapy and whole abdominal irradiation for gastric carcinoma[J]. Tumori,2008,94(4):469-473.
  • 8Jansen E P, Boot H, Saunders M P, et al. A phase Ⅰ-Ⅱ study of postoperative eapecitabine-based chemoradiotherapy in gastric cancer[J]. Int J Radiat Oncol Biol Phys, 2007,69(5):1424-1428.
  • 9Lawrence T S, Davis M A, Tang H Y, et al. Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S phase progression[J]. Int J Radiat Biol, 1996,70(3): 273-280.
  • 10胡崇明,周福有,耿明飞,宋清荣,郭海周,李剑.食管癌、贲门癌术后气胸155例原因分析及防治方法[J].实用诊断与治疗杂志,2007,21(10):798-799. 被引量:5

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部